Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03486262
Other study ID # NI16034
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date February 1, 2018
Est. completion date February 2020

Study information

Verified date February 2018
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Retrospective inclusion of lung cancers developed in a context of idiopathic pulmonary fibrosis, diagnosed and / or treated in participating centers. The cases are recovered retrospectively from the records of the pulmonology and pathology departments of our various partners.


Description:

Primary objective:

Characterize altered molecular pathways in lung cancer in patients with IPF versus lung cancer in non-IPF patients.

Secondary objectives:

Identify specific therapeutic targets Describe a cohort of lung cancers on IPF (clinical / radiological and pathological data) To study the relationship between neoplastic / preneoplastic lesions and pulmonary parenchyma reshaped by fibrosis.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 100
Est. completion date February 2020
Est. primary completion date February 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Lung carcinoma

- Idiopathic pulmonary fibrosis

Exclusion Criteria:

- No tumor sample available

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Hopital BICHAT-CLAUDE BERNARD Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Molecular profile of IPF-associated lung carcinomas Next generation sequencing of carcinomas with Ion S5 XL sequencer and Oncomineā„¢ Comprehensive Panel 1 month / 8 samples
Secondary Pathological characterization of lung carcinomas Histological classification of carcinomas and immunohistochemistry with lineage markers 1 month / 8 samples